<code id='827F1A42A2'></code><style id='827F1A42A2'></style>
    • <acronym id='827F1A42A2'></acronym>
      <center id='827F1A42A2'><center id='827F1A42A2'><tfoot id='827F1A42A2'></tfoot></center><abbr id='827F1A42A2'><dir id='827F1A42A2'><tfoot id='827F1A42A2'></tfoot><noframes id='827F1A42A2'>

    • <optgroup id='827F1A42A2'><strike id='827F1A42A2'><sup id='827F1A42A2'></sup></strike><code id='827F1A42A2'></code></optgroup>
        1. <b id='827F1A42A2'><label id='827F1A42A2'><select id='827F1A42A2'><dt id='827F1A42A2'><span id='827F1A42A2'></span></dt></select></label></b><u id='827F1A42A2'></u>
          <i id='827F1A42A2'><strike id='827F1A42A2'><tt id='827F1A42A2'><pre id='827F1A42A2'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:244
          foreign-trained health professionals
          Adobe

          The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

          The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

          advertisement

          The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          FDA clears Verve to begin U.S. study of gene
          FDA clears Verve to begin U.S. study of gene

          AdobeVerveTherapeuticssaidMondaythatithadreceivedclearancefromtheFoodandDrugAdministrationtoconducta

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Georgia court denies Trump's request to quash DA's 2020 election probe

          0:23FormerPresidentDonaldTrumpspeaksatTrumpNationalGolfClubinBedminster,N.J.,June13,2023.AndrewHarni